Progestin treatment of atypical hyperplasia and well-differentiated adenocarcinoma of the endometrium to preserve fertility

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 1037-1043

  Koskas, Martin ^a,b   Azria, Elie ^a,b   Walker, Francine ^a   Luton, Dominique ^a,b   Madelenat, Patrick ^a   Yazbeck, Chadi ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Endometrial adenocarcinoma; Endometrial atypical hyperplasia; Fertility sparing management; Progestin

Indexed keywords

CARBOPLATIN; GESTAGEN; HYDROXYPROGESTERONE; LYNESTRENOL; PACLITAXEL;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CHILDBIRTH; CLINICAL ARTICLE; COHORT ANALYSIS; CONSERVATIVE TREATMENT; DELIVERY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; INTRACYTOPLASMIC SPERM INJECTION; LIVER DYSFUNCTION; MEDICAL RECORD REVIEW; METRORRHAGIA; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURES; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; CELL DIFFERENTIATION; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY; HUMANS; HYPERPLASIA; PROGESTINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84858760520     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte MF, Bouchardy C and Petignat P: Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol 114: 448-451, 2009.
2. Kurman RJ, Kaminski PF and Norris HJ: The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. Cancer 56: 403-412, 1985. (Pubitemid 15031667)
3. Epplein M, Reed SD, Voigt LF, Newton KM, Holt VL and Weiss NS: Endometrial hyperplasia risk in relation to recent use of oral contraceptives and hormone therapy. Ann Epidemiol 19: 1-7, 2009.
4. Kempson RL and Pokorny GE: Adenocarcinoma of the endometrium in women aged forty and younger. Cancer 21: 650-662, 1968.
5. O'Neill RT: Pregnancy following hormonal therapy for adenocarcinoma of the endometrium. Am J Obstet Gynecol 108: 318-321, 1970.
6. Jadoul P and Donnez J: Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 80: 1315-1324, 2003.
7. Ercan CM, Duru NK, Sakinci M, Alanbay I, Karasahin KE and Baser I: Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system. Gynecol Endocrinol 26: 125-128, 2010.
8. Minig L, Franchi D, Boveri S, Casadio C, Bocciolone L and Sideri M: Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 22: 643-649, 2011.
9. Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, Osuga Y, Yasugi T, Kugu K, Yano T, Yoshikawa H and Taketani Y: Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett 248: 112-122, 2007.
10. Laurelli G, Di Vagno G, Scaffa C, Losito S, Del Giudice M and Greggi S: Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 120: 43-46, 2011.
11. Catherino WH and Jordan VC: Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J Steroid Biochem Mol Biol 55: 239-246, 1995.
12. Botella J, Paris J and Lahlou B: The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate. Acta endocrinologica 115: 544-550, 1987. (Pubitemid 17101084)
13. Ozdegirmenci O, Kayikcioglu F, Bozkurt U, Akgul MA and Haberal A: Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Gynecol Obstet Invest 72: 10-14, 2011.
14. Gurgan T, Bozdag G, Demirol A and Ayhan A: Preserving fertility before assisted reproduction in women with endometrial carcinoma: case report and literature review. Reprod Biomed Online 15: 561-565, 2007. (Pubitemid 350167079)
15. Corrado G, Baiocco E, Carosi M and Vizza E: Progression of conservatively treated endometrial complex atypical hyperplasia in a young woman: a case report. Fertil Steril 90: 5-8, 2008.
16. Rubatt JM, Slomovitz BM, Burke TW and Broaddus RR: Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia. Gynecol Oncol 99: 472-476, 2005. (Pubitemid 41502862)
17. Kresowik J, Ryan GL and Van Voorhis BJ: Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstet Gynecol 111: 547-549, 2008. (Pubitemid 351156496)
18. Yasuda M, Matsui N, Kajiwara H, Osamura RY, Miyamoto T, Murakami M, Shinozuka T and Itoh J: Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation. Pathol Int 54: 451-456, 2004. (Pubitemid 38829933)
19. Shamshirsaz AA, Withiam-Leitch M, Odunsi K, Baker T, Frederick PJ and Lele S: Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecol Oncol 104: 757-760, 2007. (Pubitemid 46240271)
20. Koskas M, Yazbeck C, Walker F, Clouqueur E, Agostini A, Ruat S, Lucot JP, Lambaudie E, Luton D and Madelenat P: Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res 31: 3047-3049, 2011.
21. Morice P, Fourchotte V, Sideris L, Gariel C, Duvillard P and Castaigne D: A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 96: 245-248, 2005. (Pubitemid 39612444)
22. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B and Cass I: Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 106: 693-699, 2005. (Pubitemid 41362170)
23. Fujiwara H, Ogawa S, Motoyama M, Takei Y, Machida S, Taneichi A, Ohwada M and Suzuki M: Frequency and characteristics of endometrial carcinoma and atypical hyperplasia detected on routine infertility investigations in young women: a report of six cases. Hum Reprod 24: 1045-1050, 2009.
24. Rackow BW, Jorgensen E and Taylor HS: Endometrial polyps affect uterine receptivity. Fertil Steril 95: 2690-2692, 2011.
25. Elizur SE, Beiner ME, Korach J, Weiser A, Ben-Baruch G and Dor J: Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril 88: 1562-1567, 2007. (Pubitemid 350225705)
26. Hahn HS, Yoon SG, Hong JS, Hong SR, Park SJ, Lim JY, Kwon YS, Lee IH, Lim KT, Lee KH, Shim JU, Mok JE and Kim TJ: Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 19: 1068-1073, 2009.
27. Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, Hataeg M, Kodama S, Kuzuya K, Sato S, Nishimura T, Hiura M, Nakano H, Iwasaka T, Miyazaki K and Kamura T: Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 167: 39-48, 2001. (Pubitemid 32373267)
28. Randall TC and Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 90: 434-440, 1997. (Pubitemid 27357938)
29. Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT and Given FT: Oral medroxy-progesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736-1744, 1999. (Pubitemid 29269242)
30. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M and Kamura T: Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25: 2798-2803, 2007. (Pubitemid 47123189)
31. Moore TD, Phillips PH, Nerenstone SR and Cheson BD: Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 9: 1071-1088, 1991.
32. Srkalovic G, Wittliff JL and Schally AV: Detection and partial characterization of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Res 50: 1841-1846, 1990. (Pubitemid 20098831)
33. Yu M, Yang JX, Wu M, Lang JH, Huo Z and Shen K: Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 92: 2122-2124, 2009.
34. Sodano M, Bogliatto F, Morero S, Mosso L, Torchio B and Leidi L: Case report: Successful IVF programme after conservatively treated endometrial cancer. Reprod Biomed Online 18: 578-581, 2009.